Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-30 · accession 0001104659-25-055495 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-02 | 2025-05-30 | SLS | Wasman Jane | Dir | P - Purchase | $1.69 | +20.0K | 30.4K | +192% | +$33.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-30 | P | A | 20,000 | $1.69 | 30,400 | D | — | — | (F1) The shares were purchased in multiple transactions at a price of $1.69. The reporting person undertakes to provide SELLAS Life Sciences Group, Inc., any security holder of SELLAS Life Sciences Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at the price set forth in this footnote. |